Skip to main content

Table 4 Results of the TSQM surveys

From: Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study

Items Visit 2 (n attacks = 43) Visit 3 (n attacks = 62) Visit 4 (n attacks = 84) Total (n attacks = 189)
Effectiveness (median; IQR) 67 (56–69) 56 (50–72) 67 (50–79) 67 (50–78)
Side effects (median; IQR) 100 (63–100) 100 (100–100) 100 (100–100) 100 (100–100)
• Number of attacks with side effects 16 (37%) 15 (24%) 11 (13%) 42 (22%)
Convenience (median; IQR) 50 (44–56) 50 (44–54) 50 (44–50) 50 (44–56)
Global satisfaction (median; IQR) 53 (46–69) 63 (61–69) 73 (53–85) 63 (53–83)
  1. Scores range from 0 (extremely negative) to 100 (extremely positive) for each item